Details of the Drug Combinations

General Information of This Drug (ID: DM0HS92)

Drug Name

Merimepodib DM0HS92

Synonyms

Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Approved	[1]
Gastric adenocarcinoma	2B72	Phase 3	[1]
Hepatitis C virus infection	1E51.1	Phase 2b	[2]
Head and neck cancer	2D42	Phase 2	[1]
Hepatitis virus infection	1E50-1E51	Discontinued in Phase 2	[3]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Investigative	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

2 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Pazopanib + Merimepodib	DCEOJQ4	Pazopanib	Inflammatory breast cancer	[5]
Merimepodib + Remdesivir	DC1BJAR	Remdesivir	COVID-19	[6]
------------------------------------------------------------------------------------

References

1	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022059.
2	Merimepodib, Pegylated Interferon, and Ribavirin in Genotype 1 Chronic Hepatitis C Pegylated Interferon and Ribavirin Nonresponders. Hepatology. 2009 Dec;50(6):1719-26.
3	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008158)
4	The IMPDH inhibitor merimepodib suppresses SARS-CoV-2 replication in vitro. April 09, 2020. doi: https://doi.org/10.1101/2020.04.07.028589
5	A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer. Breast Cancer Res Treat. 2013 Jan;137(2):471-82.
6	ClinicalTrials.gov (NCT04410354) Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19